COVID-19 Clinical Trial
Official title:
Phase 1b, Randomized, Open-label Study to Evaluate the Safety, Tolerability, and Immunogenicity of RVM-V001 Only, RVM-V002 Only, or RVM V001 + RVM V002 (Co Administered as Separate Injections) in Healthy Adults Previously Vaccinated With an Inactivated Virus or mRNA-based COVID-19 Vaccine in Singapore
Verified date | October 2023 |
Source | RVAC Medicines (US), Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Phase 1b, randomized, open-label, study to evaluate the safety, tolerability, and immunogenicity of RVM-V001 only, RVM-V002 only, or RVM V001 + RVM V002 (Co administered as Separate Injections) in healthy adults. The study will be conducted at one site in Singapore.
Status | Terminated |
Enrollment | 24 |
Est. completion date | September 21, 2023 |
Est. primary completion date | September 21, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 21 Years and older |
Eligibility | Inclusion Criteria: - Male and female healthy volunteers. - Aged 21 years and older on Day 1 - Judged by the investigator to be healthy based on medical history, physical examination, and vital signs evaluation at Screening visit. - Able to provide informed consent form. - Able and willing to comply with all study procedures over follow-up period of approximately 6 months. - Have documented completion of a 2-dose primary vaccination series and 1 booster vaccination with BNT162b2 OR a 3-dose primary vaccination series, with or without 1 booster dose, with an approved inactivated virus vaccine (BBIBP-CorV or CoronaVac). The last dose in all cases should have been administered at least 6 months prior to enrolment in this study. - For female subjects with childbearing potential: must agree to avoid pregnancy from 21 days prior to Day 1 until at least 90 days after the last study vaccination. Women physically capable of pregnancy (not sterilized and still menstruating or within 1 year of the last menses if menopausal) in sexual relationships with men must use an acceptable method of avoiding pregnancy during this period. Exclusion Criteria: - Received any COVID-19 vaccine other than BNT162b2, BBIBP-CorV, or CoronaVac. - Received more than 3 doses of BNT162b2 or more than 4 doses of BBIBP-CorV or CoronaVac. - Women who are pregnant or breastfeeding or intending to become pregnant; mend who will father children within the projected duration of the trial. - Positive serology test results for hepatitis C virus antibody, human immunodeficiency virus antibody, or hepatitis B viral surface antigen at Screening. - Is currently participating in or has participated in a study with an investigational product within 30 days preceding Day 1. - History of severe allergic reactions (eg, acute anaphylaxis, urticaria, skin eczema, dyspnoea, angioneurotic oedema) or other significant adverse reactions to COVID19 vaccines; allergy to known composition of RVM-001 and RVM-002. - History of coagulation dysfunction (eg, coagulation factor deficiency, coagulation disease). - Vaccinated with live attenuated vaccine within 1 month, or any other vaccine within 14 days, of Day 1 vaccination. - Received systemic immunosuppressants within 4 months prior to vaccination or an anticipated need for immunosuppressants at any time during the study. Topical or inhaled treatment is allowed if not used within 14 days prior to Day 1 vaccination. - Received blood products within 3 months prior to Day 1 vaccination. - History of alcohol or drug abuse within 3 years prior to Day 1 vaccination. - Fever (temperature > 37.5°C), dry cough, fatigue, nasal obstruction, runny nose, sore throat, myalgia, diarrhoea, shortness of breath, or dyspnoea on the day of vaccination. - Any condition that, in the opinion of the investigator, would pose a health risk to the subject if enrolled, could interfere with the evaluation of the study vaccine, or interfere with interpretation of the study results (including neurologic or psychiatric conditions deemed likely to impair the quality of safety reporting). |
Country | Name | City | State |
---|---|---|---|
Singapore | P.H. Feng Research Centre, NCID,TTSH | Singapore |
Lead Sponsor | Collaborator |
---|---|
RVAC Medicines (US), Inc. |
Singapore,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety in terms of solicited adverse events | Number of subjects with solicited adverse events | Day 1 to Day 7 inclusive | |
Primary | Safety in terms of solicited systemic adverse events | Number of subjects with solicited systemic adverse events | Day 1 to Day 7 inclusive | |
Primary | Safety in terms of unsolicited adverse events | Number of subjects with unsolicited adverse events | Day 1 to Day 28 inclusive | |
Primary | Safety in terms of SAEs, SUSARs, MAAEs and AESIs | Number of subjects with SAEs, SUSARs, MAAEs and AESIs | Day 1 to Day 180 post dose | |
Primary | Safety in terms of laboratory-based AEs | Changes in safety laboratory parameters from baseline by the Food and Drug Administration (FDA) toxicity grading scale. | Day 1 to Day 180 post dose | |
Secondary | Immunogenicity in terms of Nab | GMT of neutralizing antibody (pseudoviral neutralization assay) against Wuhan strain and BA.1 subvariant | Days 1,8,15,29 and 180 | |
Secondary | GMT of neutralizing antibody (pseudoviral neutralization assay) against Variants of Immunogenicity in terms of Nab | GMT of neutralizing antibody (pseudoviral neutralization assay) against Variants of concerns of SARS-CoV-2 | Days 1,8,15,29 and 180 | |
Secondary | Immunogenicity in terms of Humoral immune response by ELISA | GMT of serum binding antibodies (IgG) by ELISA | Days 1,8,15,29 and 180 | |
Secondary | Seroresponse rate for neutralizing antibody | SRR percentage of subjects with =4-fold increase of antibody titer over baseline | Days 8,15,29 and 180 | |
Secondary | Seroresponse rate for binding antibodies (IgG) by ELISA | SRR percentage of subjects with =4-fold increase of antibody titer over baseline | Days 8,15,29 and 180 | |
Secondary | Geometric Mean Fold Rise (GMFR) of SARS-CoV-2 Neutralizing Antibody | Days 8,15,29 and 180 | ||
Secondary | Geometric Mean Fold Rise (GMFR) of binding antibodies (IgG) by ELISA | Days 8,15,29 and 180 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT06065033 -
Exercise Interventions in Post-acute Sequelae of Covid-19
|
N/A | |
Completed |
NCT06267534 -
Mindfulness-based Mobile Applications Program
|
N/A | |
Completed |
NCT05047601 -
A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection
|
Phase 2/Phase 3 | |
Recruiting |
NCT05323760 -
Functional Capacity in Patients Post Mild COVID-19
|
N/A | |
Recruiting |
NCT04481633 -
Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection
|
N/A | |
Completed |
NCT04537949 -
A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults
|
Phase 1/Phase 2 | |
Completed |
NCT04612972 -
Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru
|
Phase 3 | |
Recruiting |
NCT05494424 -
Cognitive Rehabilitation in Post-COVID-19 Condition
|
N/A | |
Active, not recruiting |
NCT06039449 -
A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2
|
Phase 3 | |
Enrolling by invitation |
NCT05589376 -
You and Me Healthy
|
||
Completed |
NCT05158816 -
Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
|
||
Recruiting |
NCT04341506 -
Non-contact ECG Sensor System for COVID19
|
||
Completed |
NCT04512079 -
FREEDOM COVID-19 Anticoagulation Strategy
|
Phase 4 | |
Completed |
NCT04384445 -
Zofin (Organicell Flow) for Patients With COVID-19
|
Phase 1/Phase 2 | |
Completed |
NCT05975060 -
A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT05542862 -
Booster Study of SpikoGen COVID-19 Vaccine
|
Phase 3 | |
Terminated |
NCT05487040 -
A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease
|
Phase 1 | |
Withdrawn |
NCT05621967 -
Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation
|
N/A | |
Terminated |
NCT04498273 -
COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80
|
Phase 3 | |
Active, not recruiting |
NCT06033560 -
The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure
|